v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information

16. Segment Information

The Company views its operations and manages its business as one operating and reportable segment, which is the business of developing protein kinase inhibitor therapeutics. Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis using consolidated net income (loss) as a measure of profit/loss for the single reportable segment. This decision making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.

 

 

Three months ended March 31,

 

 

2025

 

 

2024

 

Costs and expenses:

 

 

 

 

 

Research and development (excluding share-based compensation) expense:

 

 

 

 

 

PAH

$

9,330,844

 

 

$

—

 

Parkinson's disease

 

142,420

 

 

 

2,343,896

 

Other programs

 

587,128

 

 

 

389,453

 

Selling, general and administrative (excluding share-based compensation)

 

3,660,282

 

 

 

1,995,577

 

Change in fair value contingent consideration

 

(1,164,864

)

 

 

—

 

Share-based compensation expense

 

2,042,196

 

 

 

53,434

 

Total costs and expenses

 

14,598,006

 

 

 

4,782,360

 

Loss from operations

 

(14,598,006

)

 

 

(4,782,360

)

Interest income

 

919,271

 

 

 

132,725

 

Net loss

$

(13,678,735

)

 

$

(4,649,635

)